News

An international team of scientists has discovered that extracts of a weedy grass called Andropogon virginicus appear to be effective against several human diseases, including diabetes and cancer.

A team of researchers from Martin Luther University Halle-Wittenberg and the University of Greifswald has developed a new inhibitor of multi-drug resistant protein 4 (MRP4). When the inhibitor was tested on drug-resistant cancer cell lines, the cancer cells began to respond to chemotherapy.

A study published in Scientific Reports explores a novel combination of CRISPR‑based gene drives to control invasive gray squirrel – Sciurus carolinensis – in the UK.

Researchers have identified new molecular mechanisms as causes for chronic skin inflammation like in atopic dermatitis (AD or neurodermatitis) and psoriasis that could provide suitable starting points for new therapies.

The ACTIV-3 clinical trial, which is evaluating the safety and efficacy of investigational therapeutics for COVID-19 in hospitalized patients, has closed enrolment in two sub-studies. The first sub-study was examining the investigational monoclonal antibody therapy VIR-7831 and the second was evaluating a combined monoclonal antibody therapy containing BRII-196 and BRII-198.

Researchers have shown that analysis of the proteomics, or all the protein data, from aggressive human cancers is a valuable strategy to identify potential novel therapeutic targets.

A new study discovered that profiling the immune landscape of cancers before therapy could help to identify patients who are likely to respond to radiotherapy straight away, and others who might benefit from priming of their tumor with immunotherapy.

Using mouse models, researchers have found that cytisine can reduce dopamine neuron loss, providing a protective effect against Parkinson's disease. Cytisine was shown to be neuroprotective in female mice, but not male mice.

A new study has shown that using theoretical models of bacterial metabolism and reproduction allows scientists to predict the type of resistance that bacteria will develop when they are exposed to antibiotics.

An international team including researchers from Bern has now been able to demonstrate in both the laboratory and in animal models why the D614G variant was able to gain the upper hand over the original SARS-CoV-2 virus.